1%, 923% and 947% respectively IgM/IgG ratio of serous inflamm

1%, 92.3% and 94.7% respectively. IgM/IgG ratio of serous inflammatory cells was higher in PBC group than in AIH group. In liver tissues, AIH cases showed predominant IgG immunostaining in portal area (66.7 %). IgM + /IgG+ ≧1 took up 100% patients in PBC group and 84.6% patients in OS group. But half of PBC cases showed slightly difference between IgG and IgM. Conclusion: IgM/IgG ratio of inflammatory cells in serum and liver biopsy tissues can be a valuable parameter for differentiating PBC from AIH. Key Word(s): 1.

autoimmune hepatitis; 2. overlap syndrome; 3. IgG; 4. IgM; Presenting Author: KITTIYOD POOVORAWAN Additional Authors: PALITTIYA SINTUSEK, NIPAPORN SIRIPON, SOMBAT TREEPRASERTSUK, PISIT TANGKIJVANICH, YONG POOVORAWAN, PIYAWAT KOMOLMIT Corresponding Author: KITTIYOD POOVORAWAN Affiliations: Faculty of Medicine, Chulalongkorn University Objective: Spleen stiffness has been found correlated with certain degrees of portal hypertension Proteases inhibitor (PHT). This study has been aimed at comparing and validating spleen stiffness measurement with and without US guidance and its correlation with clinical significance. Methods: Thirty healthy volunteers were recruited. Demographic JNK inhibitor data including weight, height and

BMI were collected. Patients were subjected to crossover measurement by fibroscan of the area between 2–4 cm below the mid axillary line at the intercostal space between the 8th and 9th rib without US guidance (Figure 1) in comparison with the ultrasound guided method. Spleen stiffness level, IQR and success rate were recorded and crossover analysis was performed. This method was applied on patients with the clinical significance of PHT. Clinical outcomes (degrees medchemexpress of esophageal varices, spleen size and platelet count) and degree of spleen stiffness were compared.

Results: Healthy males (10) and females (20) at a median age of 30 years (ranging from 22–54 years) were recruited. Median BMI was 22.1. (ranging from 16.8–35.1) Mean spleen stiffness levels were 18.3 ± 13.4 kPa and 18.4 ± 11.4 kPa (p = 0.57), mean success rates were 46.9 ± 27% and 42.4 ± 27.7% (p = 0.86), mean IQR were 4.4 ± 4.2 and 5.9 ± 6.5 (p = 0.1) applying the non US guided technique and the US guided technique, respectively. No statistically significant difference in results between these two techniques was detectable. Spleen stiffness levels were significantly correlated (r = 0.75, p < 0.01). The mean operative time was less with the non-US guided technique (5.5 min vs. 9.1 min, p = 0.05). This method was applied on 38 patients with biliary atresia and 11 patients with extra-hepatic PHT. Higher success rate (89.9 ± 18%) and less operative time (3.3 ± 3.2 minutes) were observed in these groups of patients. Degree of spleen stiffness and clinical outcomes (degrees of esophageal varices and platelet count) were significantly correlated (r = 0.57 and r = −0.64; p < 0.01, respectively).

1%, 923% and 947% respectively IgM/IgG ratio of serous inflamm

1%, 92.3% and 94.7% respectively. IgM/IgG ratio of serous inflammatory cells was higher in PBC group than in AIH group. In liver tissues, AIH cases showed predominant IgG immunostaining in portal area (66.7 %). IgM + /IgG+ ≧1 took up 100% patients in PBC group and 84.6% patients in OS group. But half of PBC cases showed slightly difference between IgG and IgM. Conclusion: IgM/IgG ratio of inflammatory cells in serum and liver biopsy tissues can be a valuable parameter for differentiating PBC from AIH. Key Word(s): 1.

autoimmune hepatitis; 2. overlap syndrome; 3. IgG; 4. IgM; Presenting Author: KITTIYOD POOVORAWAN Additional Authors: PALITTIYA SINTUSEK, NIPAPORN SIRIPON, SOMBAT TREEPRASERTSUK, PISIT TANGKIJVANICH, YONG POOVORAWAN, PIYAWAT KOMOLMIT Corresponding Author: KITTIYOD POOVORAWAN Affiliations: Faculty of Medicine, Chulalongkorn University Objective: Spleen stiffness has been found correlated with certain degrees of portal hypertension BAY 80-6946 (PHT). This study has been aimed at comparing and validating spleen stiffness measurement with and without US guidance and its correlation with clinical significance. Methods: Thirty healthy volunteers were recruited. Demographic Small molecule library data including weight, height and

BMI were collected. Patients were subjected to crossover measurement by fibroscan of the area between 2–4 cm below the mid axillary line at the intercostal space between the 8th and 9th rib without US guidance (Figure 1) in comparison with the ultrasound guided method. Spleen stiffness level, IQR and success rate were recorded and crossover analysis was performed. This method was applied on patients with the clinical significance of PHT. Clinical outcomes (degrees 上海皓元 of esophageal varices, spleen size and platelet count) and degree of spleen stiffness were compared.

Results: Healthy males (10) and females (20) at a median age of 30 years (ranging from 22–54 years) were recruited. Median BMI was 22.1. (ranging from 16.8–35.1) Mean spleen stiffness levels were 18.3 ± 13.4 kPa and 18.4 ± 11.4 kPa (p = 0.57), mean success rates were 46.9 ± 27% and 42.4 ± 27.7% (p = 0.86), mean IQR were 4.4 ± 4.2 and 5.9 ± 6.5 (p = 0.1) applying the non US guided technique and the US guided technique, respectively. No statistically significant difference in results between these two techniques was detectable. Spleen stiffness levels were significantly correlated (r = 0.75, p < 0.01). The mean operative time was less with the non-US guided technique (5.5 min vs. 9.1 min, p = 0.05). This method was applied on 38 patients with biliary atresia and 11 patients with extra-hepatic PHT. Higher success rate (89.9 ± 18%) and less operative time (3.3 ± 3.2 minutes) were observed in these groups of patients. Degree of spleen stiffness and clinical outcomes (degrees of esophageal varices and platelet count) were significantly correlated (r = 0.57 and r = −0.64; p < 0.01, respectively).

The idea of a surgical “solution” to migraine is inherently attra

The idea of a surgical “solution” to migraine is inherently attractive to patients. Interest in surgical approaches to migraine has been motivated by serendipitous improvement in headaches noted in patients who have undergone various plastic surgery

“forehead rejuvenation” procedures. These procedures are based on the premise that contraction of facial or other muscles impinges on peripheral branches of the trigeminal nerve. The procedures involved are often referred to collectively as “migraine deactivation surgery,” although a variety of surgical sites and procedures are involved. These include resection of the corrugator supercilii muscle with the placement of fat grafts in the Endocrinology antagonist site, “temporal release” procedures involving dissection of the glabellar area, transection of the zygomatical temporal branch of the trigeminal nerve, and resection of the semispinalis capitus muscle with placement of fat grafts in the area with the aim of reducing pressure on the occipital nerve.

Finally, some surgeons also perform nasal septoplasty or otherwise attempt to address possible intranasal trigger points.[17] Because the decision about which surgical procedure to perform is often made on an individual basis, it is difficult to objectively study the outcomes of surgery. When initial surgery is unsuccessful, patients may undergo additional procedures to deactivate other trigger points. Patients are often selected for surgery on the basis of improvement BMN 673 price in headaches with the injection of OnabotulinumtoxinA and/or occipital nerve blockade, on the theory that response to such temporary procedures is proof of nerve impingement.[18] 上海皓元 However, there is limited evidence to support the view that such surgery is effective or safe. Several randomized studies have been performed, but these have serious methodological weaknesses. Additionally, most studies in the literature have been performed by the same group of surgical proponents and published

in a single subspecialty journal.[18, 21] Despite the lack of good quality evidence about the balance of benefits and harms from surgical treatments of migraine, the procedures are becoming more common. A recent survey of members of the American Society of Plastic Surgeons found that 18% of respondents had performed migraine surgery. Sixty percent of those who had not performed the surgery said they “would be interested if an appropriate patient was referred to them by a neurologist.”[19] The American Headache Society has issued a statement urging “patients, healthcare professionals and migraine treatment specialists themselves, to exercise caution in recommending or seeking such therapy.” This statement went on to say “In our view, surgery for migraine is a last-resort option and is probably not appropriate for most sufferers. To date, there are no convincing or definitive data that show its long-term value.

Vasospasm after rupture of a DAVF, however, has not previously be

Vasospasm after rupture of a DAVF, however, has not previously been reported. A 48-year-old woman who presented with the sudden onset of altered mental status. Imaging demonstrated extensive subarachnoid hemorrhage and spinal DAVF at C1 to C2. The patient underwent a

suboccipital craniotomy for DAVF ligation. On post-operative day three, she began having acute weakness in all her extremities with proprioception and vibration preserved, whereas pain and temperature sensation was lost. An angiogram demonstrated bilateral vertebral artery vasospasm with no filling of the anterior spinal artery. Bilateral angioplasty of the vertebral arteries was performed successfully and post-angioplasty, the right vertebral artery was filling the anterior spinal artery. The patient clinically improved. learn more She subsequently required treatment with n-butyl cyanoacrylic acid (nBCA) embolization and gamma knife radiosurgery to Staurosporine in vitro achieve obliteration of the lesion. For patients with subarachnoid hemorrhage

of unknown origin, differential diagnosis should include DAVF. This patient also presented with vasospasm in the context of ruptured DAVF, a complication previously unreported in the literature. This finding suggests that close monitoring for vasospasm after rupture of DAVF is warranted. Approximately 60-80% of acquired spinal vascular lesions are dural arteriovenous fistulas (DAVFs).[1] DAVFs are abnormal vascular formations found between a dural branch of a radicular artery and a vein along the spinal dural surface, most often at the intervertebral

foramen near the nerve root.[1-3] Spinal DAVFs may arise at any spinal level from the foramen magnum to the sacrum, but are most often found at the thoracolumbar junction.[3] In 34-45% of cases presented in the literature, craniocervical DAVF lesions have been associated with subarachnoid hemorrhage (SAH).[1, 4, 5] In none of these cases was the finding of vasospasm reported. We present what we believe is the first reported case of a patient with vasospasm secondary to a spinal DAVF. The complexity of treating this MCE公司 lesion is discussed and a review of the literature is undertaken. This 48-year-old woman presented with the sudden onset of altered mental status. Computed tomography (CT) scanning of the head revealed extensive SAH and intraventricular hemorrhage with hydrocephalus (Fig 1). A CT angiogram revealed a 1 cm left DAVF at the C1 arch level (Fig 1). The patient had emergent external ventriculostomy placed. A diagnostic angiogram showed a left-sided DAVF fed by more than one vascular branch; the largest supply was the vertebral artery (VA) just below the foramen magnum, while another branch was seen to extend from a spinal artery originating at the vertebrobasilar confluence (Fig 1). The patient underwent a suboccipital craniotomy and C1-2 laminectomy for ligation of the AVF. The feeding artery was cauterized and clipped.


“Background Mother-to-child transmission (MTCT) of hepatit


“Background Mother-to-child transmission (MTCT) of hepatitis B virus(HBV)

still remains a world concerned question. Previous studies have demonstrated the effectiveness of telbivudine (LdT) and lamivudine (LAM) in pregnancy, but there were few data about tenofovir (TDF), also it is a controversal problem on the GW-572016 solubility dmso choice of antiviral drugs and the appropriate time to start therapy. Purpose To evaluate the safety and reliability of tenofovir in preventing mother-to-child transmission of HBV during pregnancy. Methods We totally enrolled 38 HBV infected pregnant women with HBsAg and HBeAg positive since 8/2009 until 5/2013. Among these patients, 21 women were treated with TDF (300mg/d) alone; 11 were treated with TDF (300mg/d) +LDT (600mg/d), while 6 were treated with TDF (300mg/d)

+LAM (100mg/d) during pregnancy. All the babies were injected with hepatitis B vaccine and immunoglobulin according to the standard protocal after birth. Mothers co-infected with other liver diseases were excluded from the study. Results In our study, 13 mothers started treatment at the first trimester (0-11 weeks); and 4 began treatment at PLX4032 ic50 the second trimester (15-24 weeks); while 21 started treatment at the third trimester (28-39 weeks). Five mothers were with ALT elevation before treatment which ranged from 1.8×ULN to 12.2×ULN and 2 of them decreased to normal level at delivery. All the infants cordblood were detected negative for HBV DNA and born with no congenital diseases. All babies were detected negative for HBsAg and HBV DNA at 20-48 weeks . Conclusion It is safe and effective by using tenofovir MCE公司 in prevent mother-to-child transmission of HBV during the whole pregnancy. Disclosures: The following people have nothing to disclose: Hongfei Huang, Quanxin Wu, Yuming Wang

Background: AASLD treatment guideline for CHB recommends ALT ≥ two times the upper limit of normal (ULN) as one of the major criteria to initiate antiviral therapy. However, patients with ALT < 2× ULN may not be free from future risk of liver complications such as hepatocellular carcinoma (HCC). Our aim is to compare the risk of HCC for non-cirrhotic CHB patients by an ALT levels and by treatment status. Method: We performed a retrospective cohort study of 1814 consecutive treatment-naïve, noncirrhotic CHB patients aged 40 or older whose follow-up was 12 months or longer from 1991-2014 at four U.S. medical clinics. ALT of ≥2× ULN was defined by gender (≥60 for men, ≥ 38 for women). Survival analysis with Kaplan Meier curves were produced to capture the rate of HCC development by ALT level and in those who were treated versus those who remained untreated. Annual incidence was reported in cases per 1000 person-years. Results: The majority of patients were males (59%), had HBeAg-negative status (85%), and had a mean age of 52.5 ± 9.8. Median years of follow-up was 4 (1-10) years.

Eighteen patients were given a reduction dose of ribavirin that d

Eighteen patients were given a reduction dose of ribavirin that decreased by one tablet per day compared to the standard group (reduction group). Results:  Of the 33 study patients, no patient stopped the treatment due to treatment-related adverse learn more events. The dose of IFN-β was reduced in three patients: Two patients belonged to the standard group and one patient belonged to the reduction group. The dose of ribavirin was reduced in 11 patients during combination therapy: nine patients belonged to the standard group and two patients belonged to the reduction group. The sustained virological

response (SVR) was 72.2% (13/18) in the reduction group and 80.0% (12/15) in the standard group. There was no significant difference in SVR rate between Ceritinib supplier the reduction and standard groups (P = 0.699). Conclusion:  The reduction therapy of IFN-β and ribavirin in elderly chronic hepatitis C patients with genotype 2 and high virus load is one selection of treatment. “
“Background and Aims:  Barrett’s esophagus (BE) is reported to be infrequent in Asians, with no data from India regarding its prevalence and risk factors. We investigated the frequency and risk factors of columnar mucosa with or without specialized intestinal metaplasia (SIM) in Indian patients with gastroesophageal reflux disease (GERD). Methods:  A total of 278 GERD patients over 2 years underwent

gastroscopy and completed a questionnaire MCE公司 for possible BE risk factors. Patients with columnar mucosa on endoscopy underwent four-quadrant biopsy; BE was histologically defined as columnar mucosa with or without SIM. Patients without columnar mucosa at endoscopy were considered as controls and compared to patients with BE and those with SIM. Results:  Forty-six patients with GERD had columnar mucosa on histology (16.54%); 25 (8.99%) of these had SIM. The risk factors for BE were the presence of hiatus hernia (odds ratio [OR]: 3.14;

95% confidence interval [CI]: 1.2–8.17) and a history of eructation (OR: 2.28; CI: 1.11–4.66). The risk factors for SIM were age ≥ 45 years (OR: 2.63; CI: 1.03–6.71), hiatus hernia (OR: 3.95; CI: 1.24–12.56), and a history of eructation (OR: 3.41; CI: 1.19–9.78). Sex, severity of symptoms, dietary factors, tobacco or alcohol use, and body mass index were not associated with BE. The median circumferential segment length was 2 (1–10) cm, and the maximal length was 3 (2–11) cm in both groups. Conclusion:  BE is not an uncommon finding among Indian GERD patients. Age ≥ 45 years, history of eructation, and the presence of hiatus hernia are associated with SIM. “
“Prednisolone is a corticosteroid that has been used to treat inflammatory liver diseases such as autoimmune hepatitis and alcoholic hepatitis. However, the results have been controversial, and how prednisolone affects liver disease progression remains unknown.

Eighteen patients were given a reduction dose of ribavirin that d

Eighteen patients were given a reduction dose of ribavirin that decreased by one tablet per day compared to the standard group (reduction group). Results:  Of the 33 study patients, no patient stopped the treatment due to treatment-related adverse HM781-36B nmr events. The dose of IFN-β was reduced in three patients: Two patients belonged to the standard group and one patient belonged to the reduction group. The dose of ribavirin was reduced in 11 patients during combination therapy: nine patients belonged to the standard group and two patients belonged to the reduction group. The sustained virological

response (SVR) was 72.2% (13/18) in the reduction group and 80.0% (12/15) in the standard group. There was no significant difference in SVR rate between find more the reduction and standard groups (P = 0.699). Conclusion:  The reduction therapy of IFN-β and ribavirin in elderly chronic hepatitis C patients with genotype 2 and high virus load is one selection of treatment. “
“Background and Aims:  Barrett’s esophagus (BE) is reported to be infrequent in Asians, with no data from India regarding its prevalence and risk factors. We investigated the frequency and risk factors of columnar mucosa with or without specialized intestinal metaplasia (SIM) in Indian patients with gastroesophageal reflux disease (GERD). Methods:  A total of 278 GERD patients over 2 years underwent

gastroscopy and completed a questionnaire 上海皓元医药股份有限公司 for possible BE risk factors. Patients with columnar mucosa on endoscopy underwent four-quadrant biopsy; BE was histologically defined as columnar mucosa with or without SIM. Patients without columnar mucosa at endoscopy were considered as controls and compared to patients with BE and those with SIM. Results:  Forty-six patients with GERD had columnar mucosa on histology (16.54%); 25 (8.99%) of these had SIM. The risk factors for BE were the presence of hiatus hernia (odds ratio [OR]: 3.14;

95% confidence interval [CI]: 1.2–8.17) and a history of eructation (OR: 2.28; CI: 1.11–4.66). The risk factors for SIM were age ≥ 45 years (OR: 2.63; CI: 1.03–6.71), hiatus hernia (OR: 3.95; CI: 1.24–12.56), and a history of eructation (OR: 3.41; CI: 1.19–9.78). Sex, severity of symptoms, dietary factors, tobacco or alcohol use, and body mass index were not associated with BE. The median circumferential segment length was 2 (1–10) cm, and the maximal length was 3 (2–11) cm in both groups. Conclusion:  BE is not an uncommon finding among Indian GERD patients. Age ≥ 45 years, history of eructation, and the presence of hiatus hernia are associated with SIM. “
“Prednisolone is a corticosteroid that has been used to treat inflammatory liver diseases such as autoimmune hepatitis and alcoholic hepatitis. However, the results have been controversial, and how prednisolone affects liver disease progression remains unknown.

6 The predominant literature on NRH is in the form of case report

6 The predominant literature on NRH is in the form of case reports or small case series and there are

only few reports of portal pressure measurements in this condition. In the current issue of the Journal, Bissonnette et al.8 reported hemodynamic measurements, including HVPG, in 21 patients and portal vein pressure gradient (PVPG, portal vein pressure – inferior vena cava pressure) in 12 patients with NRH. The causes of NRH in these patients included oxaliplatin chemotherapy, treatment with purine antagonists, liver transplantation, hematological and rheumatological conditions, and HIV infection. click here Fifteen out of 21 patients with varices/ascites had HVPG less than 10 mm Hg suggesting a pre-sinusoidal portal hypertension, which was confirmed by a portal vein pressure higher than 12 mm Hg in all 12 patients. Though the majority of patients (15/21) had a pre-sinusoidal component, six patients did have higher HVPG (more

than 10 mm Hg) suggesting sinusoidal portal hypertension.8 These data by Julien et al. thus suggest that both components of portal hypertension (pre-sinusoidal and sinusoidal) occur in patients with NRH. The pre-sinusoidal portal hypertension is related to the well-described vasculopathy (obliterative portal venopathy), while the sinusoidal portal hypertension is probably attributable to sinusoidal obstruction because of compression by regenerative nodules.8 Even though data are sparse, selleck inhibitor other studies in patients with NRH have also suggested a mixed type of portal hypertension (pre-sinusoidal and sinusoidal).

MCE In one of the case reports, a 47-year-old woman with NRH who underwent HVPG before and after splenectomy had a marked difference between WHVP and FHVP with little difference between portal venous pressure and WHVP; these findings indicated that portal hypertension in NRH was primarily sinusoidal.9 Similar data were shown by two other studies, one another single case report and the other a series of 13 cases.4,10 On the other hand, in a relatively large number of biopsy-proven cases of NRH (n = 14), Arvanitaki and Adler5 suggested that portal hypertension in patients with NRH was pre-sinusoidal. The clinical manifestations included splenomegaly, esophageal varices and variceal bleeding.5 In another recent study, 26 patients receiving 6-thioguanine for inflammatory bowel disease were evaluated with HVPG and liver biopsy.11 Six out of 24 patients (25%) with adequate liver tissue on histology had evidence of NRH. Of six patients with NRH, three had elevated (> 5 mm Hg) HVPG, two with HVPG > 10 mm Hg, whereas three others had HVPG < 5 mm Hg in spite of having clinical manifestations of portal hypertension.

28-064-μm size range in mediating ALF syndrome The direct corre

28-0.64-μm size range in mediating ALF syndrome. The direct correlation between MP number and factor VIII levels also suggests that MPs may play a role in vascular endothelial cell activation/injury of ALF, the severity of which directly correlates with mortality.10, 33 Whether MPs serve as mediators of the systemic complications of ALF or are simply biomarkers of inflammation cannot be determined KU-60019 chemical structure conclusively from our data; however, it appears likely that they represent both the cause and the effect of systemic inflammation. Recent studies have

also incriminated MPs in the pathogenesis of chronic liver diseases (CLDs).30 Patients with cirrhosis have increased circulating MPs derived from leukocytes, ECs, and hepatocytes, compared to healthy controls, and concentrations of MPs increase with increasing severity of cirrhosis.20 MPs isolated from PPP of subjects with cirrhosis were shown in vitro and in experimental animals to impair Aloxistatin supplier vasoconstrictor response and may thereby cause the vasoplegia of end-stage liver disease. Similarly, T-lymphocyte-derived CD4+ and CD8+

MP numbers were higher in patients with nonalcoholic fatty liver disease and chronic hepatitis C than healthy controls and correlated with disease activity.34, 35 In contrast to the present work, the number of CD41+ (platelet-derived) MPs in these populations with CLD were not significantly higher than healthy controls nor were they proportional to the severity of disease. However, both of these studies were performed using flow cytometry and

may have thereby missed a possible effect of platelet-derived MPs, most of which (as shown herein) are below the limit of detection by flow cytometry. These studies and the present work suggest that increased production of platelet MPs may be restricted to acute conditions characterized by a prominent SIRS. In addition to systemic effects of MPs implied by the association of MP concentrations and systemic complications of ALF, procoagulant MPs may also 上海皓元医药股份有限公司 serve to exacerbate the primary liver injury. In a mouse model of APAP hepatotoxicity, activation of coagulation within the necrotic liver increases the primary APAP-induced injury and is greatly ameliorated by heparin administration.7 Furthermore, the prothrombotic effect of APAP is also greatly ameliorated in mice expressing low levels of TF, providing indirect evidence that liver-derived TF may mediate the activation of coagulation.7 Other experimental models also support a role for secondary activation of coagulation within the acutely injured liver in the pathogenesis of liver failure.36, 37 Because thrombin generation requires exposure of anionic phospholipids on cellular and/or MP surfaces, intrahepatic MPs would be reasonable candidate platforms on which coagulation occurs. MP-TF assays have also shown that the population of circulating MPs is highly procoagulant in a TF-dependent manner.

Primary endpoint was clinical response at wk6 in patients enrolle

Primary endpoint was clinical response at wk6 in patients enrolled after dose selection. Secondary endpoints at wk6 were clinical remission, mucosal healing, and change from baseline in IBDQ. Primary analysis population for efficacy consisted of patients randomized after dose selection (n = 774); for safety, all treated patients in Ph2 and 3 were combined (n = 1065). Results: 774 patients were randomized in the primary analysis population; 759 patients (98%) completed through wk6. Significantly higher proportions of patients http://www.selleckchem.com/GSK-3.html who received GLM were in clinical response, clinical remission, mucosal healing and showed improvement in the IBDQ at wk6 vs PBO

(Table). Through wk6, proportions of patients with AEs Proteases inhibitor were similar for the combined GLM and PBO grps (39.1% and 38.2%, resp); 3.0% and 6.1% of patients, resp, had SAEs. There was a death in the GLM 400 mg/200 mg grp; a single case of demyelination was reported in this grp. Injection site reactions were uncommon and comparable across GLM grps. Malignancy rates were 0.3%. 0.0%, and 0.3% in the PBO, GLM 200 mg/100 mg, and GLM 400/200 mg grps, resp. Conclusion: Induction regimens

of SC GLM induced clinical response, clinical remission, mucosal healing and improved quality of life in anti-TNF naïve UC patients. Safety of GLM induction was consistent with the safety profile of GLM in labeled rheumatologic indications and other anti-TNFs. Key Word(s): 1. golimumab; 2. ulcerative colitis; 3. induction; 4. anti-TNF; Table: Primary and major secondary endpoints at wk6 among randomized patients after dose selection     GLN   PBO 200 mg/100 mg 400 mg/200 mg 3 patients prospectively excluded

from efficacy analyses due to misconduct; their safety data is included 133 (51.8%) p < 0.0001* 142(55.0%) p < 0.0001* 48(18.7%) p < 0.0001 46(17.8%) p < 0.0001 111(43.2%) p = 0.0005 117(45.3%) p < 0.0001 27.4 p < 0.0001 27.0 p < 0.0001 Presenting Author: XIAOCANG CAO Additional Authors: ZHIBO HAN Corresponding Author: XIAOCANG CAO Affiliations: tianjin medicl university general hospital; Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union of Medical MCE College Objective: MSCs have been found to have significant immunosuppressive capacities which make it as a potential treatment for various immune disorders including IBD. Many studies are being performed to further elucidate the mechanism of immune modulation by MSCs, while the effect molecule seems different between the cell of human and mice. Furthermore, MSCs pretreated by proinflammatory cytokines such as INFr and TNFa obtain intensive immunoregulatory effect, thus far the qualification of activated MSCs is still unclear, especially for human cell, which limits farther exploration. Here, we just defined hMSChireg, a subpopulation of human mesenchymal stem cells with character of CD106+, which exhibits unique immune regulatory property.